AbbVie
Imbruvica combo scores expanded FDA approval in most common adult form of leukaemia
January 29, 2019Manufacturing and Production, Sales and Marketing AbbVie, Cancer, Janssen, imbruvica, leukaemia, pharma
It’s big news for Janssen and AbbVie as it emerged that their jointly-developed Bruton’s tyrosine kinase (BTK) inhibitor Imbruvica (ibrutinib) …
Top Ten most popular articles on Pharmafile.com this week!
January 25, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AbbVie, Celgene, NHS, health, pharma, venlytxo
While American firm AbbVie gained approval for leukaemia drug Venlytxo, the NHS defeated the US multinational thus week in court, …
AbbVie’s case against the NHS thrown out of court
January 22, 2019Manufacturing and Production AbbVie, HCV, NHS, health, hepatitis C, public health
A judge has thrown US multinational AbbVie’s case against NHS England’s hepatitis C procurement process, out of court. Mr Justice …
Abbvie’s chronic lymphocytic leukaemia drug Venclytxo scores greenlight from NICE
January 18, 2019Medical Communications, Sales and Marketing AbbVie, NHS, NICE, Venclyxto, leukaemia, pharma
A new recommendation from NICE means that thousands of patients in England and Wales will be able to receive Abbvie’s …
AbbVie records an estimated $4billion in impairment charges after failure of cancer drug Rova-T
January 8, 2019Manufacturing and Production AbbVie, M&A, MA, Stemcentrx, acquisition, rova-t
US firm AbbVie has said that it will record an estimated $4 billion in impairment charges related to the abandonment …
AbbVie’s Venclyxto combo beats standard of care in chronic lymphocytic leukaemia
December 3, 2018Research and Development, Sales and Marketing ASH 2018, AbbVie, Cancer, Venclyxto, leukaemia, pharma
AbbVie has taken the opportunity at the American Society of Hematology (ASH) Annual Meeting 2018 to reveal new data on …
NHS to save £300 million by switching to Humira biosimilars
November 27, 2018Manufacturing and Production, Sales and Marketing AbbVie, Humira, Mylan, NHS, Sandoz, adalimumab, biosimilars, pharrma
NHS England has announced that the health service is set to save £300 million by switching to biosimilar versions of …
German health minister Jens Spahn calls for faster adoption of biosimilars
November 14, 2018Research and Development AbbVie, Germany, biosimilars, jens Spahn
Germany’s health minister Jens Spahn has called for faster uptake of biosimilars in an effort to cut the cost of …
AbbVie sue NHS over hepatitis C drug procurement
November 8, 2018Business Services AbbVie, NHS, britain, court, hep C, hepatitis, ruling
American pharma firm AbbVie are suing Britain’s NHS after claiming that the health service’s procurement of hepatitis C drugs breached …
NICE issues draft guidance rejecting Abbvie’s Venclyxto in chronic lymphocytic leukaemia
October 26, 2018Medical Communications, Sales and Marketing AbbVie, NHS, NICE, leukaemia, pharma, venetoclax
It’s bad news for patients in the UK affected by chronic lymphocytic leukaemia (CLL) as the National Institute of Health …
GSK named third best UK workplace
October 22, 2018Sales and Marketing AbbVie, Amgen, BMS, Eli Lilly, GSK, J&J, JJ, work
British multinational GlaxoSmithKline has been rated as the third best company to work for in the UK, according to jobs …
Top Ten most popular articles on Pharmafile.com this week
August 17, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AbbVie, CMO, Litigation, OxyContin, Purdue Pharma, approvals, top 10
This week’s pharmaceutical headlines were dominated by legal spats as the state of New York sued OxyContin drug maker Purdue …
Chicago Judge overturns $140 million AbbVie AndroGel verdict
August 13, 2018Sales and Marketing AbbVie, Litigation, androgel, legal, testosterone
A US Judge has overturned a $140.1 million verdict against the New York-listed AbbVie Inc. The verdict, which ruled in …
FDA approves first endometriosis pain management drug in a decade
July 25, 2018Research and Development, Sales and Marketing AbbVie, FDA, Neurocrine Biosciences, endometriosis, pharma
The FDA has confirmed its approval of AbbVie and Neurocrine Biosciences’ Orilissa (elagolix), a nonpeptide small molecule gonadotropin-releasing hormone (GnRH) …
AbbVie and Mylan reach US marketing agreement for Humira biosimilar
July 18, 2018Research and Development, Sales and Marketing AbbVie, Humira, Mylan, US, pharma
AbbVie and Mylan have announced that they have both signed a licensing agreement for the former’s proposed biosimilar version of …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
